PLoS ONEMolecular BiologyPeer-reviewed journal article
A nonsense mutant of the hepatitis B virus large S protein antagonizes multiple tumor suppressor pathways through c-Jun activation domain-binding protein1
Shu-Yi Chiu, Hsiang-Ju Chung, Ya‐Ting CheniD, Min‐Syuan Huang, Chien‐Chih HuangiD, Shiu-Feng Kathy HuangiD, Isao MatsuuraiD
- Citations
- 1
- FWCI
- 0.19
- Field percentile
- top 49%
Abstract
Hepatitis B virus (HBV) is a major cause of hepatocellular carcinoma (HCC). Previous studies have identified recurrent nonsense mutations in the HBV large S (LHBs) gene from the liver from HBV core antigen-positive HCC patients. These nonsense mutants have been shown to be oncogenic in mouse xenograft models using a mouse embryonic fibroblast cell line. Here, we expressed in a liver cell line Huh-7 a carboxy terminally truncated protein from a nonsense mutant of the LHBs gene, sW182* (stop codon at tryptophane-182). Although the sW182* protein appeared not to be very stable in the cultured liver cells, we confirmed that the protein can be highly expressed and retained for a prolonged period of time in the hepatocytes in the mouse liver, indicating its stable nature in the physiological condition.\n\nIn the Huh-7 cells, the sW182* mutant downregulated tumor suppressors p53 and Smad4. This downregulation was reversed by a proteasome inhibitor MG132, implying the involvement of proteasome-based protein degradation in the observed regulation of the tumor suppressors. On the other hand, we found that c-Jun activation domain-binding protein 1 (Jab1) physically interacts with the sW182*, but not wild-type LHBs. RNA interference (RNAi) of Jab1 restored the levels of the downregulated p53 and Smad4. The sW182* mutant inhibited the promoter activity of downstream target genes of the tumor suppressors. Consistently, Jab1 RNAi reversed the inhibition.\n\nThese results suggest that the LHBs nonsense mutant antagonizes the tumor suppressor pathways through Jab1 in the liver contributing to HCC development.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Chemical-induced degradation of PreS2 mutant surface antigen reverses HBV- mediated hepatocarcinogenesis
J. Y. Yang, Y.-H. Wu, … L. Wang·bioRxiv·Jan 24, 2022
- HBV rewires liver cancer signaling by altering PP2A complexes
A. Pitea, R. Turnham, … J. Gordan·bioRxiv·Mar 15, 2023
- RNA Helicase DDX5 Negatively Regulates Wnt Signaling and Hepatocyte Reprogramming in Hepatitis B Virus-related Hepatocellular Carcinoma
S. K. Kailasam Mani, Z. Cui, … O. Andrisani·bioRxiv·Sep 12, 2019
- Patient-Derived Mutant Forms of NFE2L2/NRF2 Drive Aggressive Murine Hepatoblastomas
H. Wang, J. Lu, … E. V. Prochownik·bioRxiv·Sep 13, 2020
- Mechanistic basis for targeting homologous recombination defective liver cancer via synthetic lethality
- The HBV basal core promoter mutation confers a replicative advantage and transcriptionally reprograms hepatocytes toward HCC subtypes
Leon Louis Seifert, Georgios Dangas, … Ype P. de Jong·bioRxiv·Sep 23, 2026